GLP-1；Metformin；Telomere-telomerase System；Par-4
Conditions
Keywords
telomere-telomerase, Par-4, GLP-1, metformin
Brief summary
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
Detailed description
160 Type 2 diabetes in our hospital will divide into 4 groups: group A (40 healthy volunteers), group B (40 patients who give basal and insulin treatment, group C（40 patients who give basal and Liraglutide treatment),group D（40 patients who give basal and metformin treatment). The age, height, weight, blood glucose, glycosylated hemoglobin A1c（HbA1c）,homeostasis model assessment(HOMA-IR), lipid, blood pressure, course of disease, telomere length,telomerase activity will record respectively. And High-sensitive C-reactive protein (HsCRP), Par-4, GST,SOD,GSH-PX,ATF-6,CHOP,XBP-1 and Tumor necrosis factor-α（TNF-α） will detect as Baseline. After each group's treatment, Change from baseline of all indexes will record, Multifactor logistic regression will be analyzed the correlations between each positive indexes.
Interventions
DRUGLiraglutide
GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
DRUGMetformin
Metformin(1500mg-2000mg/day) treatment for 6 months
Sponsors
Third Military Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Newly dignosised type 2 diabetes according to WHO criteria.glycated hemoglobin (HbA1c) was more than 10%; * Seronegative for antibodies against insulin, islet cells and glutamic acid decarboxylase (GAD);
Exclusion criteria
* Type 1 diabetes mellitus,presence of autoimmune diabetes indicated by antibodies to insulin, islet cells, and GAD； * Gestational diabetes; * patients with heart, liver, or renal function impairment;presence of severe infections or cerebrovascular disease;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| physiological parameter:glycosylated hemoglobin A1c | up to 6 months; | up to 6 months;;HbA1c was measured by a certified hospital laboratory according to established and approved protocols |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| physiological parameter:the concentration of Par-4 | up to 6 months; | up to 6 months;;secretary Par-4 were detected with Par-4 ELISA kit (MBL, USA) |
| physiological parameter:telomere length | up to 6 months; | up to 6 months;;Telomere length was measured via fluorescence in situ hybridization using flow cytometry |
| physiological parameter:telomease activity | up to 6 months; | up to 6 months;;Telomerase activity was measured using the TeloTAGGG Telomerase PCR ELISAPLUS kit (Roche Diagnostics, Mannheim, Germany) |
| physiological parameter:TNF-α | up to 6 months; | up to 6 months, TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;TNF-a levels were measured by commercial ELISA kit following the manufacturer's instructions;(MBL, USA) |
Countries
China
Outcome results
None listed